Emerging protein kinase inhibitors for treating pancreatic cancer.

about

Emerging protein kinase inhibitors for treating pancreatic cancer.

Item

http://www.wikidata.org/entity/Q39158411

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Emerging protein kinase inhibitors for treating pancreatic cancer.

@en

Emerging protein kinase inhibitors for treating pancreatic cancer.

@nl

type

Item

label

Emerging protein kinase inhibitors for treating pancreatic cancer.

@en

Emerging protein kinase inhibitors for treating pancreatic cancer.

@nl

prefLabel

Emerging protein kinase inhibitors for treating pancreatic cancer.

@en

Emerging protein kinase inhibitors for treating pancreatic cancer.

@nl

P1476

Emerging protein kinase inhibitors for treating pancreatic cancer.

@en

P2093

Fumio Nagashima

http://www.w3.org/2001/XMLSchema#string

Junji Furuse

http://www.w3.org/2001/XMLSchema#string

P2860

Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

Cancer-related inflammation

STATs in cancer inflammation and immunity: a leading role for STAT3

Cancer statistics, 2016

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

P304

77-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14728214.2017.1293648

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28253828

http://www.w3.org/2001/XMLSchema#string